Fifth Third Bancorp Trims Stake in BioNTech SE (NASDAQ:BNTX)

Fifth Third Bancorp lessened its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 26.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 414 shares of the company’s stock after selling 148 shares during the quarter. Fifth Third Bancorp’s holdings in BioNTech were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Fred Alger Management LLC purchased a new position in BioNTech during the third quarter valued at approximately $59,485,000. Baillie Gifford & Co. boosted its holdings in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after buying an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in BioNTech by 63.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after buying an additional 7,340 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in BioNTech by 123.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after acquiring an additional 33,375 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several research analyst reports. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. TD Cowen cut their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Canaccord Genuity Group raised their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Finally, Truist Financial assumed coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $123.77 on Monday. The company has a 50 day simple moving average of $117.34 and a two-hundred day simple moving average of $107.33. The stock has a market cap of $29.67 billion, a price-to-earnings ratio of -58.94 and a beta of 0.18. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.73 earnings per share. As a group, analysts predict that BioNTech SE will post -3.77 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.